Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Wilmington Savings Fund Society FSB

Wilmington Savings Fund Society FSB trimmed its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.4% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 50,287 shares of the medical research company’s stock after selling 1,767 shares during the period. Wilmington Savings Fund Society FSB’s holdings in Thermo Fisher Scientific were worth $26,161,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. AMF Tjanstepension AB acquired a new position in shares of Thermo Fisher Scientific in the 3rd quarter valued at about $42,409,000. Brookstone Capital Management increased its stake in Thermo Fisher Scientific by 3.1% in the 3rd quarter. Brookstone Capital Management now owns 2,558 shares of the medical research company’s stock valued at $1,582,000 after buying an additional 76 shares during the period. Daymark Wealth Partners LLC boosted its stake in shares of Thermo Fisher Scientific by 14.5% during the 3rd quarter. Daymark Wealth Partners LLC now owns 709 shares of the medical research company’s stock valued at $439,000 after buying an additional 90 shares during the period. CWM LLC increased its stake in shares of Thermo Fisher Scientific by 91.3% in the third quarter. CWM LLC now owns 35,114 shares of the medical research company’s stock worth $21,720,000 after acquiring an additional 16,756 shares during the last quarter. Finally, Wedmont Private Capital raised its holdings in shares of Thermo Fisher Scientific by 14.2% during the third quarter. Wedmont Private Capital now owns 2,338 shares of the medical research company’s stock worth $1,400,000 after acquiring an additional 291 shares in the last quarter. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Down 0.2 %

Shares of TMO stock opened at $571.44 on Friday. The stock has a market cap of $218.58 billion, a P/E ratio of 34.57, a price-to-earnings-growth ratio of 3.18 and a beta of 0.77. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. The stock has a fifty day moving average price of $546.51 and a 200 day moving average price of $571.95. Thermo Fisher Scientific Inc. has a one year low of $493.30 and a one year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, topping analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. Analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific announced that its board has approved a stock buyback plan on Friday, November 15th that authorizes the company to buyback $4.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to repurchase up to 2% of its shares through open market purchases. Shares buyback plans are usually a sign that the company’s board of directors believes its shares are undervalued.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Evercore ISI cut their price target on Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. Raymond James reaffirmed an “outperform” rating and set a $667.00 price objective (up previously from $650.00) on shares of Thermo Fisher Scientific in a research report on Monday, February 3rd. Scotiabank increased their price target on shares of Thermo Fisher Scientific from $605.00 to $650.00 and gave the stock a “sector perform” rating in a research note on Monday, February 3rd. UBS Group lifted their price objective on shares of Thermo Fisher Scientific from $700.00 to $715.00 and gave the company a “buy” rating in a research note on Friday, January 31st. Finally, Bank of America cut their target price on Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating on the stock in a report on Friday, December 13th. Four research analysts have rated the stock with a hold rating and nineteen have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $658.00.

Insiders Place Their Bets

In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $530.26, for a total transaction of $5,302,600.00. Following the sale, the chief executive officer now owns 111,192 shares in the company, valued at approximately $58,960,669.92. This represents a 8.25 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total transaction of $175,677.00. Following the transaction, the executive vice president now owns 16,363 shares in the company, valued at approximately $9,582,009.17. This trade represents a 1.80 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 20,125 shares of company stock worth $11,231,699 over the last three months. 0.34% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.